Markets
markets

Texas Instruments tumbles after CFO affirms loss of sales momentum after a rush of buying to beat tariffs

Texas Instruments is tumbling after its chief financial officer reiterated that strength in the chipmaker’s sales through April included a rush to beat potential tariffs, and that its momentum has slowed since then.

At Citi’s 2025 Global TMT Conference on Thursday, CFO Rafael Lizardi said:

“The aging orders inside the quarter, which are a good leading indicator, those were pretty strong January through April. And April in particular were really strong and we think some of that was due to the Liberation Day and some of the dynamics that happened there. But then things did slow down after April, or at least didn’t grow as they normally would have month-on-month, and month-on-month again, some of that was the Liberation Day potential pull-ins, and we talked about that at some length at our July earnings release call.”

The comments are adding to investors’ fears that Texas Instruments’ nascent turnaround may be somewhat of a mirage.

CEO Haviv Ilan wasn’t especially definitive in that July conference call on how much demand may have been pulled forward because of customer fears they’d soon face much higher costs due to tariffs:

“We don’t know. I just want to repeat that point. We just have to make assumptions. Customers don’t tell us why they order. We just go through the data and try to decipher it, right? So we just can’t rule out the possibility. And we say there likely could have been some. When you see such a strong behavior in Q2 versus Q1, you have to attribute some of it to the tariff environment.”

Back in June, we flagged that Texas Instruments was one of a handful of companies seemingly very susceptible to having seen a somewhat one-off boost to orders because of changing consumer demand in light of the changing rules of cross-border commerce.

In fact, the main complaint about Texas Instruments’ latest quarterly report from the sell-side community was simply that the vibes were off. Three separate analysts on the conference call noted that, despite financials that were better than expected and relatively solid guidance, Ilan’s “tone” was not too upbeat.

And, speaking of the tone being off...

When asked about inventory management and avoiding any write-offs, Lizardi was willing to countenance the idea that Texas Instruments’ sales in its next fiscal year may be on the softer side of what the chipmaker has penciled in.

“We have a framework for next year’s revenue, $20 billion to $26 billion; we put that out there. If we’re at the lower end of that framework for next year, and you’ll hear more about that in October and January... then we’ll have to adjust our wafer starts down to manage our inventory better,” he said during today’s Q&A.

This is a qualified statement, not a formal tweak to the company’s outlook, but certainly not a particularly encouraging tone to be striking. The Street is already seemingly bracing for a cut to that guidance, as 2026 revenue forecasts currently stand at $19.5 billion, per Bloomberg.

More Markets

See all Markets
markets

Robinhood, AppLovin, and Emcor pop on announcement of addition to S&P 500

Shares of Robinhood Markets, AppLovin, and Emcor are all rallying in post-market trading on Friday upon news that they’re being added to the S&P 500.

Shares of the brokerage popped 7.2%, the adtech company rose 7.8%, and the construction company was up a more modest 2.7% in the minutes following the announcement.

(Robinhood Markets, Inc. is the parent company of Sherwood Media, an independently operated media company subject to certain legal and regulatory restrictions.)

Strategy, another stock rumored to be in the running for inclusion in the benchmark US stock index that has been passed over, sank 2.5% in postmarket trading.

markets

Kenvue plunges after reports suggest RFK Jr. may try to link prenatal Tylenol use to autism

Kenvue sank 15% Friday after a WSJ report said Health and Human Services Secretary Robert F. Kennedy Jr. may attempt to link prenatal Tylenol use to autism in an upcoming government report.

Kenvue, the maker of Tylenol and formerly a division of Johnson & Johnson prior to a 2023 spin-out, pushed back, saying the science shows “no causal link” between acetaminophen use during pregnancy and autism, and pointed to FDA and medical groups that agree on the drug’s safety.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

markets

Lucid surges following 6 days of losses after headlines misidentify Cantor Fitzgerald’s lower split-adjusted price target as a good thing

It’s been a shortened week, but still a rough one for Lucid. Investor blowback to the luxury EV maker’s 1-for-10 reverse stock split has sent shares to all time lows this week.

After six straight days of closing lower, Wall Street appears to have decided enough is enough and is loading up on Lucid shares on Friday, sending them up 13% in recent trading. As of 2:10pm eastern, Lucid trading volumes were at more than 240% of their 30 day average.

Some of the move could be attributed to traders reading headlines that don’t take into consideration Lucid’s reverse split. Cantor Fitzgerald on Friday slapped a new price target on Lucid of $20, compared to its previous target of $3. Some news outlets (not us!) presented that as an increase. The problem: With the 1-for-10 reverse split in effect, a comparable price target would have been $30. The new $20 target is actually... a cut.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.